Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis: Update Bulletin [May 2017]

Product Code:
596200719
Publication Date:
May 2017
Format:
PDF
Price:
€1265

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus (ocrelizumab, Roche/Biogen) as a therapy for relapsing and primary progressive forms of MS; AB Science announcing that its oral tyrosine kinase inhibitor, masitinib, has passed the two-year non-futility test in a Phase III trial; and Apitope announcing positive results from a Phase IIa clinical trial of ATX-MS-1467, a peptide-based therapy with potential in MS.

Business Questions:

  • According to KOLs, what are the chances of Ocrevus being approved with the same broad label in the EU?
  • How likely is it that Ocrevus be prescribed off-label?
  • Which product(s) will be most impacted by Ocrevus’ launch?
  • What are KOLs’ opinions regarding masitinib and where in the treatment paradigm would such an agent be used?
  • How clinically attractive is Apitope’s ATX-MS-1467?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved